Temtokibart

替托奇拜单抗

Report date: 2024/02/05 13:36:35

Base Information

Drug NameTemtokibart
Drug Alias NameARGX-112LEO-138559LP-0145
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin-22 receptor antagonists
TargetsInterleukin-22Interleukin-22 receptor
Therapy Area/IndicationsDermatitis, Atopic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaCanadaUnited States +[13] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesArgenx SeLeo Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesLeo Pharma Consultancy(Shanghai)Company LtdLeo Pharma IncLeo Pharma A/S
Inactive CompaniesN/A
Active IndicationsDermatitis, Atopic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A